logo

Science

Targeted therapies tailored to disease biology.

Our Approach

Our precision medicine approach pairs deep immunological insights with human genetics, helping to define immune-mediated diseases (IMDs) by their molecular and cellular signatures.

Understanding the causal cellular drivers of disease allows us to rapidly advance programs from early discovery through clinical development, with a focus on reaching patients that are most likely to benefit from our novel therapeutic agents.

Many IMDs stem from the dysfunction of cells that make up the immune system. Our initial therapeutic programs target, modulate or deplete these cellular drivers of disease. Different IMDs often share the same cellular drivers of disease, and we aim to expand each of our programs to multiple other indications in the IMD landscape.

Plasma cellsarrow down
Neutrophils
Mast cells
Plasma cells
Plasmablasts and plasma cells are the body’s primary antibody-secreting cells, implicated in autoantibody-mediated diseases such as membranous nephropathy (MN) and IgA nephropathy (IgAN).

Our Pipeline

At HI-Bio, we are bringing a fresh perspective to develop treatments for IMDs through our clinical-stage programs and pipeline.

Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
Science graphics_Plasma cell.pngFelzartamab

PLA2R+ Membranous Nephropathy

Phase 2
Franchise / Cell TypePlasma cell
Target / Molecule NameCD38 / Felzartamab

Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as PLA2R+ Membranous Nephropathy, through their production of autoantibodies.

StagePhase 2
Clinical Trials
Commercial Rights

HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.

IgA Nephropathy

Phase 2
Franchise / Cell TypePlasma cell
Target / Molecule NameCD38 / Felzartamab

Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as IgA Nephropathy, through their production of autoantibodies.

StagePhase 2
Clinical Trials
Commercial Rights

HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.

Antibody Mediated Transplant Rejection

Phase 2
Franchise / Cell TypePlasma cell
Target / Molecule NameCD38 / Felzartamab

Felzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma cells, which are believed to drive certain diseases, such as Antibody Mediated Transplant Rejection, through their production of autoantibodies.

StagePhase 2
Clinical Trials
Commercial Rights

HI-Bio holds executive worldwide rights for felzartamab with the exception of Greater China.

Science graphics_Neutrophil.pngHIB210

Undisclosed

IND Enabling
Franchise / Cell TypeNeutrophil
Target / Molecule NameC5aR1 / HIB210

HIB210 is an anti-C5aR1 antibody with the potential to be a best-in-class therapy for complement-mediated diseases including ANCA Associated Vasculitis (AAV), Hidradenitis Suppurativa, C3 Glomerulonephropathy and Lupus Nephritis. When compared to existing agents, it has shown greater activity against neutrophils, a cell type key to driving several IMDs.

StageIND Enabling
Clinical Trials
Commercial Rights

HI-Bio holds exclusive worldwide rights for HIB210 with the exception of Greater China and South Korea for HIB210.

Science graphics_Mast cell.pngMast Cell Program

Undisclosed

Discovery
Franchise / Cell TypeMast cells
Target / Molecule NameUndisclosed

We are advancing discovery programs targeted at dysfunction of mast cells implicated in several indications. 

StageDiscovery

Our Toolkit

Our precision immunology toolkit helps translate insights that emerge from our ongoing research and development efforts. Through efforts to profile the immune phenotypes that drive IMDs, HI-Bio’s translational toolkit has the potential to address multiple diseases with high unmet medical needs throughout the IMD landscape.

The four pillars of the HI-Bio toolkit:

Human genetics

Identifying and validating targets, discovering causal biomarkers and optimizing patient selection

Human immunophenotyping

Assessing the role of select targets and establishing biomarker strategies to increase confidence in our therapeutics and define patient subsets for any given indication

Data sciences

Deriving insights with emerging computational methods

Therapeutic engineering

Engineering fit-for-purpose biologics optimized for IMDs

Contact Us
info@hibio.com